hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 01:37:24 - browse：251

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

Medtronic CEO on promising devices for diabetes, hypertension

Readout Newsletter: New research from Sanofi, Regeneron, etc.

CRISPR gene editing developments we’re watching in 2024

Chimpanzees, like humans and whales, get menopause: Study

What STAT readers think about the FDA and patient advocacy

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Eli Lilly to pay $200M for Beam’s stake in gene

Peter Hotez and the public health issue of online harassment

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Peter Hotez and the public health issue of online harassment

How to keep neuroscience’s past racism from being its future

Wildfire smoke exposes gaps in outdoor worker protections

Medtronic CEO on promising devices for diabetes, hypertension

Dobbs anniversary: the lost opportunity of abortion as health care

David Ricks of Eli Lilly: best biopharma CEO of 2023

focus

Senate panel to vote on hospitals, PBMs, prisoner care

Cassava reveals details — and problems — with Alzheimer's study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Can sheer will power keep patients alive in their dying hours?

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Paying for Covid pills will soon shift to insurers

explore

focus

hotspot

Wikipedia